USA flag logo/image

An Official Website of the United States Government

Kainate Receptor Antagonists to Treat Neuropathis Pain

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
39570
Program Year/Program:
1998 / SBIR
Agency Tracking Number:
39570
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Bearsden Bio, Inc.
34 MT PLEASANT DR Frazer, PA 19014
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1998
Title: Kainate Receptor Antagonists to Treat Neuropathis Pain
Agency: HHS
Contract: N/A
Award Amount: $744,554.00
 

Abstract:

The development of novel compounds that regulate specific subtypes of glutamate receptors for the treatment of CNS disorders is the major goal of Symphony Pharmaceuticals, Inc. Symphony discovered a novel series of heterocyclic 1,2-dihydrophthalazines that selectively antagonize AMPA receptors and protect animals in seizure models. Our hypothesis is that a 1 ,2-dihydrophthalazine AMPA receptor antagonist would be a safe and clinically useful drug for the treatment of seizure disorders such as epilepsy. Phase I specific aims are to: 1) Synthesize the individual stereo isomers of SYM 2206 and two non-chiral-center containing analogs of SYM 2206. 2) Test each new analog for its ability to protect mice and rats against seizures at non-toxic doses. 3) Select a compound for preclinical toxicology and pharmacokinetic evaluation in Phase II of the proposal. The work in Phase Il is expected to complete the preclinical development of one of the compounds. Phase III will comprise clinical trials for the treatment of epilepsy or other seizure disorders.

Principal Investigator:

Sturgess, michael a
0

Business Contact:


2153867630
Small Business Information at Submission:

Bearsden Bio, Inc.
600 Swedesford Rd Frazer, PA 19104

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No